Anti-Cisplatin modified DNA, Recombinant [CP9/19]
Invented by Dr Michael Tilby at Absolute Antibody University of Newcastle upon Tyne The Institute of Cancer Research
![Sonicated DNA was prepared from yeast strain (No-247) BY4742 treated with Cisplatin (2.5 mM, 4 hour incubation). Immunoprecipitation was performed using an increasing amount of anti-Cisplatin modified DNA [CP9/19] (top panel) and anti-Cisplatin modified DNA, Recombinant [CP9/19] (lower panel). Fold enrichment over no antibody control is shown on the Y axis with the amount of antibody indicated (in ug) on the X axis. Data kindly provided by Drs. Simon Reed and Shuvro Prokash Nandi.](https://res.cloudinary.com/ximbio/image/upload/c_thumb,fl_lossy,h_124,q_auto,r_max,w_124/45302546-aa2c-4b57-b0a6-546b671978b3.jpg)
Anti-Cisplatin modified DNA [CP9/19]
Invented by Dr Michael Tilby from University of Newcastle upon Tyne
Invented at The Institute of Cancer Research , University of Newcastle upon Tyne
- Datasheet
- References (27)
- Inventor Info
Info
| Catalogue Number | 151464 |
| Applications | ELISA FACS IHC IP DB |
| Antigen/Gene or Protein Targets | Cisplatin modified native DNA |
| Reactivity | N/A |
| Relevance |
This antibody enables the quantification of cisplatin-induced adducts on DNA. This antibody has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines. Antibody CP9/19 recognises only the intra-strand cross-links formed by cisplatin between adjacent purines. |
| Host | Rat |
| Immunogen | Cisplatin modified native DNA |
| Positive Control | RNA/DNA |
| Subclass | IgG2a |
| Myeloma Used | Y3.AG.1.2.3 |
| Recommended Growing Conditions | DMEM + 10%FCS + Glu + Pen/Strep |
| Notes | Alternative Name: ICR4 |
| Research Area | DNA Damage and Repair, Epigenetics & Nuclear Signalling |
References: 27 entries
Powell et al. 2015. Sci Rep. 5:7975. PMID: 25609656.
IP
3D-DIP-Chip: a microarray-based method to measure genomic DNA damage.
Europe PMC ID: 25609656
Kothandapani et al. 2012. Exp Cell Res. 318(16):1973-86. PMID: 22721696.
Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.
Europe PMC ID: 22721696
Kothandapani et al. 2011. J Biol Chem. 286(16):14564-74. PMID: 21357694.
Novel role of base excision repair in mediating cisplatin cytotoxicity.
Europe PMC ID: 21357694
Meczes et al. 2005. Biochem Pharmacol. 70(12):1717-25. PMID: 16259963.
Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA.
Europe PMC ID: 16259963
Deverman et al. 2002. Cell. 111(1):51-62. PMID: 12372300.
Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage.
Europe PMC ID: 12372300
Veal et al. 2001. Clin Cancer Res. 7(8):2205-12. PMID: 11489793.
Veal et al. 2001. Clin Cancer Res. 7(8):2205-12. PMID: 11489793.
Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
Europe PMC ID: 11489793
Strobeck et al. 2000. Proc Natl Acad Sci U S A. 97(14):7748-53. PMID: 10884406.
BRG-1 is required for RB-mediated cell cycle arrest.
Europe PMC ID: 10884406
Ghazal-Aswad et al. 1999. Ann Oncol. 10(3):329-34. PMID: 10355578.
Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.
Europe PMC ID: 10355578
Welters et al. 1999. Ann Oncol. 10(1):97-103. PMID: 10076728.
The potential of plantinum-DNA adduct determination in ex vivo treated tumor fragments for the prediction of sensitivity to cisplatin chemotherapy.
Europe PMC ID: 10076728
Peng et al. 1997. Br J Cancer. 76(11):1466-73. PMID: 9400943.
Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Europe PMC ID: 9400943
Cross et al. 1996. Int J Cancer. 66(3):404-8. PMID: 8621265.
Effect of quercetin on the genotoxic potential of cisplatin.
Europe PMC ID: 8621265
Evans et al. 1994. Cancer Res. 54(6):1596-603. PMID: 8137265.
Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation.
Europe PMC ID: 8137265
Tilby et al. 1991. Cancer Res. 51(1):123-9. PMID: 1703029.
Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.
Europe PMC ID: 1703029
Add a reference
References: 27 entries
Powell et al. 2015. Sci Rep. 5:7975. PMID: 25609656.
IP
3D-DIP-Chip: a microarray-based method to measure genomic DNA damage.
Kothandapani et al. 2012. Exp Cell Res. 318(16):1973-86. PMID: 22721696.
Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.
Kothandapani et al. 2011. J Biol Chem. 286(16):14564-74. PMID: 21357694.
Novel role of base excision repair in mediating cisplatin cytotoxicity.
Meczes et al. 2005. Biochem Pharmacol. 70(12):1717-25. PMID: 16259963.
Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA.
Deverman et al. 2002. Cell. 111(1):51-62. PMID: 12372300.
Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage.
Veal et al. 2001. Clin Cancer Res. 7(8):2205-12. PMID: 11489793.
Veal et al. 2001. Clin Cancer Res. 7(8):2205-12. PMID: 11489793.
Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
Strobeck et al. 2000. Proc Natl Acad Sci U S A. 97(14):7748-53. PMID: 10884406.
BRG-1 is required for RB-mediated cell cycle arrest.
Ghazal-Aswad et al. 1999. Ann Oncol. 10(3):329-34. PMID: 10355578.
Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.
Welters et al. 1999. Ann Oncol. 10(1):97-103. PMID: 10076728.
The potential of plantinum-DNA adduct determination in ex vivo treated tumor fragments for the prediction of sensitivity to cisplatin chemotherapy.
Peng et al. 1997. Br J Cancer. 76(11):1466-73. PMID: 9400943.
Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Cross et al. 1996. Int J Cancer. 66(3):404-8. PMID: 8621265.
Effect of quercetin on the genotoxic potential of cisplatin.
Evans et al. 1994. Cancer Res. 54(6):1596-603. PMID: 8137265.
Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation.
Tilby et al. 1991. Cancer Res. 51(1):123-9. PMID: 1703029.
Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.
Add a reference
